GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

GSK

1,858.5

-0.83%↓

Search

AstraZeneca PLC

Fechado

SetorSaúde

13,514 -3.07

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13514

Máximo

13632

Indicadores-chave

By Trading Economics

Rendimento

1.6B

3.9B

Vendas

-215M

15B

P/E

Médio do Setor

27.389

51.415

EPS

1.29

Rendimento de Dividendos

1.75

Margem de lucro

25.602

Funcionários

96,100

EBITDA

1.1B

5.7B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+17.01% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.75%

2.34%

Próximos Ganhos

27 de jul. de 2026

Próxima data de ex-dividendo

6 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-8.7B

282B

Abertura anterior

13517.07

Fecho anterior

13514

Sentimento de Notícias

By Acuity

26%

74%

53 / 345 Ranking em Healthcare

AstraZeneca PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de abr. de 2026, 16:28 UTC

Ganhos

Correction to AstraZeneca Update

29 de abr. de 2026, 15:11 UTC

Ganhos

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

29 de abr. de 2026, 06:31 UTC

Ganhos

AstraZeneca Gets Revenue Boost From Cancer Drugs

27 de mar. de 2026, 10:04 UTC

Notícias Principais

Oil Climbs Higher, Stock Recovery Fades as Doubts Cloud Cease-Fire Hopes

13 de mai. de 2026, 12:29 UTC

Conversa de Mercado

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

13 de mai. de 2026, 11:54 UTC

Conversa de Mercado

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

1 de mai. de 2026, 09:31 UTC

Conversa de Mercado

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

29 de abr. de 2026, 10:29 UTC

Conversa de Mercado
Ganhos

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

29 de abr. de 2026, 10:06 UTC

Conversa de Mercado
Ganhos

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29 de abr. de 2026, 09:53 UTC

Conversa de Mercado
Ganhos

AstraZeneca Seems in Fine Health -- Market Talk

29 de abr. de 2026, 06:05 UTC

Ganhos

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

29 de abr. de 2026, 06:04 UTC

Ganhos

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

29 de abr. de 2026, 06:04 UTC

Ganhos

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

29 de abr. de 2026, 06:03 UTC

Ganhos

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

29 de abr. de 2026, 06:03 UTC

Ganhos

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

29 de abr. de 2026, 06:02 UTC

Ganhos

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

29 de abr. de 2026, 06:01 UTC

Ganhos

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

29 de abr. de 2026, 06:01 UTC

Ganhos

AstraZeneca Backs 2026 View

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Adj EPS $2.58

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Rev $15.29B

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Pretax Pft $3.91B

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Oper Pft $4.25B

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q Net Pft $3.08B

29 de abr. de 2026, 06:00 UTC

Ganhos

AstraZeneca PLC 1Q EPS $1.97

27 de abr. de 2026, 10:48 UTC

Conversa de Mercado

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

10 de abr. de 2026, 11:57 UTC

Conversa de Mercado

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

10 de abr. de 2026, 10:26 UTC

Conversa de Mercado
Ganhos

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

2 de abr. de 2026, 09:16 UTC

Conversa de Mercado

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

27 de mar. de 2026, 10:40 UTC

Conversa de Mercado

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

27 de mar. de 2026, 10:17 UTC

Conversa de Mercado

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

Comparação entre Pares

Variação de preço

AstraZeneca PLC Previsão

Preço-alvo

By TipRanks

17.01% parte superior

Previsão para 12 meses

Média 16,076.92 GBX  17.01%

Máximo 18,600 GBX

Mínimo 11,300 GBX

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para AstraZeneca PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

15 ratings

13

Comprar

1

Manter

1

Vender

Sentimento

By Acuity

53 / 345 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
help-icon Live chat